- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04743934
Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer (RAD 2003)
RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
More than 40,000 men with prostate cancer in the United States will begin androgen deprivation therapy (ADT) each year. ADT is an important part of treatment, because it improves survival for men with metastatic or high-risk localized disease, and reduces rates of biochemical progression for men with intermediate-risk localized disease who receive radiation. The most common ADT agents modulate gonadotropin-releasing hormone to suppress the downstream testosterone production, resulting in testosterone levels similar to those observed following surgical castration (<20 ng/dL). Since male sexual interest is highly correlated with serum testosterone levels, loss of sexual interest is nearly universal among men who receive ADT.Sexual dysfunction is the most common complaint among men with prostate cancer and contributes to lower overall quality of life (QoL) experienced by men receiving ADT. Furthermore, the loss of sexual interest experienced during ADT is highly distressing for men with prostate cancer and their partners, which contributes additional psychological morbidity in these patients.
Flibanserin is approved for treatment of female hypoactive sexual desire disorder, and the safety profile of 100mg daily flibanserin is well described in premenopausal women.The safety profile of flibanserin in healthy men has been assessed in multiple phase I clinical trials, but has not been evaluated among men receiving ADT for prostate cancer.
This is a phase II randomized, double-blinded, placebo-controlled clinical trial designed to provide an initial estimate of the efficacy of flibanserin to promote sexual interest in men with prostate cancer receiving androgen suppression therapy and to confirm the safety profile. This study will take place at a single academic comprehensive cancer center.
Following confirmation of eligibility, participants who are enrolled in this study are randomized to receive daily flibanserin 100mg or placebo for a 12-week period.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Andrew McDonald, MD
- Phone Number: (205) 934-5670
- Email: flibanserinstudy@uabmc.edu
Study Contact Backup
- Name: Amanda Smith
- Phone Number: (205) 644-1340
- Email: flibanserinstudy@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- Amanda Smith
-
Contact:
- Amanda Smith
- Phone Number: 205-644-1340
- Email: flibanserinstudy@uabmc.edu
-
Contact:
- Kate Heinzman
- Phone Number: 2056441340
- Email: flibanserinstudy@uabmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Ability to take oral medication and be willing to adhere to the study regimen.
- Male age >18 years.
- Histologically confirmed prostate cancer.
- Currently receiving gonadotropin releasing hormone agonist/antagonist monotherapy.
- Serum testosterone <50 ng/dL.
- Serum AST and ALT less than 2 times upper limit of normal.
- Endorsed reduced sexual interest.
- Attempted intercourse.
- Current sexual partner.
- Was sexually active with partner within 6 months prior to ADT.
- No other antineoplastic therapy planned during study period.
- No active symptoms attributable to systemic prostate cancer.
Exclusion Criteria:
- Current systemic prostate cancer treatment besides GnRH agonist/antagonist, anti-androgens, or abiraterone.
- Prior to ADT had erections not firm enough for intercourse despite use of pharmacologic agents such as phosphodiesterase-5 inhibitors.
- Current symptoms attributable to active prostate cancer
- Moderate or heavy alcohol use (>2 drinks/day)
- Concurrent moderate or strong CYP3A4 inhibitors
- Concurrently taking medication classified as a monoamine oxidase inhibitor.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Flibanserin + ADT
Flibanserin at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
|
Flibanserin 100mg tablets taken by mouth daily at bedtime
Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
|
Placebo Comparator: Placebo + ADT
Placebo at 100mg by mouth once daily at bedtime while receiving androgen deprivation therapy (ADT).
|
Androgen deprivation therapy consisting of a GnRH agonist or antagonist, choice of agent at discretion of treating physician.
Visually identical placebo tablets taken by mouth daily at bedine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-reported frequency of attempting sexual intercourse
Time Frame: Baseline up to 12 weeks
|
The number of patients in each arm reporting attempting sexual intercourse at least 3 times in the prior month (0-2 attempts vs. 3+ attempts) will be compared using the two-group chi-square test, or Fisher's exact test if the assumptions for the chi-square test are not tenable.
|
Baseline up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sexual Quality of Life (QoL)
Time Frame: Up to 12 weeks
|
Determined using T-scores (higher T-score indicates better QoL) from the PROMIS v2.0 Brief Sexual Function and Satisfaction (Male) form and comparing T-score between patients receiving flibanserin and patients receiving placebo.
|
Up to 12 weeks
|
Frequency of physician-assessed grade 3+ Adverse Events
Time Frame: Baseline up to 12 weeks
|
Toxicity will be assessed by a physician investigator and scored using the CTCAE v5.0 scale.
|
Baseline up to 12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Andrew McDonald, MD, University of Alabama at Birmingham (UAB)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300006880
- 5R21CA259808-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Adenocarcinoma
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Puerto Rico
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University of California, San FranciscoCompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Switzerland
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7United States
-
Andrei IagaruCompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate AdenocarcinomaUnited States
Clinical Trials on Flibanserin 100 MG
-
Genuine Research Center, EgyptBio Med for Pharmaceuticals Industries (BIOMED), EgyptCompleted
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalUnited States
-
Sprout Pharmaceuticals, IncTerminatedDepression | Sexual Dysfunctions, PsychologicalUnited States
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalUnited States, Canada
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalUnited States, Canada
-
Sprout Pharmaceuticals, IncTerminatedSexual Dysfunctions, PsychologicalUnited States, Canada
-
Sprout Pharmaceuticals, IncCompletedSexual Dysfunctions, PsychologicalUnited States, Canada
-
Sprout Pharmaceuticals, IncTerminatedSexual Dysfunctions, PsychologicalUnited States, Canada
-
Mohit KheraSprout Pharmaceuticals, IncRecruiting
-
Sprout Pharmaceuticals, IncTerminatedSexual Dysfunctions, PsychologicalUnited States, Canada